Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04254575 · ClinicalTrials.gov registry record
Understanding Daily Changes in BDD Risk Using Smartphones
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 87
- Enrollment target
NCT04254575: Completed study, sponsored by Massachusetts General Hospital.
NCT04254575 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04254575 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time-sensitive, and ecologically valid measures of key risk factors for suicide and substance misuse in BDD: negative affect states. As next steps, this research can be extended to detect risk transdiagnostically, with the goal of enabling just-in-time interventions to target suicide and substance misuse across psychiatric illnesses.
Primary Outcome
Ecological momentary assessment (EMA) of anxiety intensity, where higher scores indicated more severe anxiety.
Interventions
- OTHER None, observational study only (no interventions)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2023-04-28 |
What the finished NCT04254575 record still lists
NCT04254575 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which None, observational study only (no interventions) is the first listed.
NCT04254575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04254575 about?
NCT04254575 is a clinical study titled "Understanding Daily Changes in BDD Risk Using Smartphones". Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time...
What is the current status of trial NCT04254575?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2020-07-15. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT04254575?
The interventions under investigation include: None, observational study only (no interventions) (OTHER).
Who is sponsoring clinical trial NCT04254575?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI